Evidence map›Paper›PMID 26205665›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2015

Risk factors for and impact of carbapenem-resistant Acinetobacter baumannii colonization and infection: matched case-control study.

O Henig, G Weber, M B Hoshen, M Paul, L German, A Neuberger, I Gluzman, A Berlin, C Shapira, R D Balicer

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Microorganisms · 2022
    Article
  10. Article
  11. Antibiotic-ResistantAntibiotics (Basel, Switzerland) · 2021
    Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Risk factors for acquisition of carbapenem-resistance during treatment with carbapenem in the intensive care unit: a prospective study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019
    Observational
  17. Article
  18. Article
  19. Article
  20. The difference in medical costs between carbapenem-resistant Acinetobacter baumannii and non-resistant groups: a case study from a hospital in Zhejiang province, China.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

O HenigInfectious Disease Unit, Lady Davis Carmel Medical Center, 7 Michal Street, Haifa, Israel. oryan.henig@gmail.com.
G WeberInfectious Disease Unit, Lady Davis Carmel Medical Center, 7 Michal Street, Haifa, Israel.
M B HoshenClalit Research Institute, Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel.
M PaulDivision of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel.
L GermanClalit Research Institute, Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel.
A NeubergerDivision of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel.
I GluzmanClalit Research Institute, Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel.
A BerlinClalit Research Institute, Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel.
C ShapiraTechnion Faculty of Medicine, Haifa, Israel.
R D BalicerClalit Research Institute, Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of this investigation was to identify risk factors for carbapenem-resistant Acinetobacter baumannii (CRAB) and its association with mortality. A population-based matched case-control study using the computerized database of Clalit Health Services (CHS) in the period between 2007 and 2012 was conducted. Hospitalized patients with CRAB colonization or infection were compared to hospitalized patients without evidence of A. baumannii, matched by age, ward of hospitalization, season, Charlson score, and length of hospitalization. Risk factors for CRAB isolation were searched for using multivariate analysis. Association of CRAB and other risk factors with mortality were assessed in the cohort. A total of 1190 patients with CRAB were matched to 1190 patients without CRAB. Low socioeconomic status was independently associated with CRAB isolation and CRAB bacteremia [odds ratio 2.18, 95% confidence interval (CI) 1.02-5]. Other risk factors were invasive procedures and bacteremia with other pathogens prior to CRAB isolation, and various comorbidities. Among all patients, CRAB isolation was independently associated with increased mortality (hazard ratio 2.33, 95% CI 2.08-2.6). Socioeconomic status is associated with health outcomes. Our population-based study revealed an almost doubled risk for CRAB in patients at lower socioeconomic status and an association with healthcare exposure. CRAB was associated with mortality and might become a risk indicator for complex morbidity and mortality.

Indexed as

Acinetobacter baumanniiAcinetobacter InfectionsAdultAgedAged, 80 and overAnti-Bacterial AgentsCarbapenemsCase-Control StudiesCohort StudiesCross InfectionDrug Resistance, Multiple, BacterialFemaleHumansIsraelMaleMicrobial Sensitivity TestsAnti-Bacterial AgentsCarbapenems

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.